Anavex Life Sciences Corp (AVXL)

[JB3729]

The article you provided a link to was from April, 2015. At that time Biogen's drug showed some early promise. The $2.5 billion total cost included all trials and a four year construction project to build a new manufacturing facility.

Since then -

UPDATED: In a setback, Biogen's mid-range dose of aducanumab flops in Alzheimer's study
http://www.fiercebiotech.com/r-d/updated-a-setback-biogen-s-mid-range-dose-of-aducanumab-flops-alzheimer-s-study


Phase 3 oncology trials average around $40,000 per patient according to this - http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf

Most oncology trials involve IV dosing and/or radiation. Alz trials should be much cheaper with the patient sitting at home taking a pill and going in for testing once every 3 months.

In spite of that, let's use $40,000 per patient times 300 (Missling's highest estimated number of patients for phase 3) to figure cost of A2-73 phase 3 -

$40,000 X 300 = $12 million

Let's double that (600 patients) = $24 million

Let's double that again (1,200 patients) = $48 million